Insilico Medicine, a Boston-based biotech firm, has reached a valuation exceeding $1 billion, marking its entry into the unicorn club. This milestone follows a successful $110 million Series E funding round led by Value Partners Group. The company specializes in using artificial intelligence to enhance drug discovery processes and develop therapeutic programs from the ground up.
Insilico's innovative approach includes utilizing transformer diffusion models to target both aging and diseases simultaneously. The company has recently made strides in treating pulmonary fibrosis, showcasing the potential of its AI-driven methodologies. Additionally, Insilico is venturing into humanoid robotics to automate laboratory tasks, further enhancing its research capabilities.
• Insilico Medicine surpasses $1 billion valuation, joining unicorn ranks.
• AI models target aging and diseases, enhancing drug discovery.
These models help Insilico understand complex biological processes over time, aiding drug discovery.
Insilico utilizes AI to streamline the development of new therapeutic programs from inception.
Insilico Medicine employs AI to accelerate drug discovery and develop innovative therapeutics.
Value Partners Group led Insilico's Series E funding round, supporting its AI-driven initiatives.
The Wall Street Journal 2month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.